Navigation Links
Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension
Date:2/23/2011

ST. LOUIS, Feb. 23, 2011 /PRNewswire/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today the first-ever use of its Niobe® Magnetic Navigation System in a renal artery ablation procedure for the treatment of chronic hypertension that was not treatable with medication.  This procedure was performed by Petr Neuzil, MD, PhD, Head of Cardiology and Director of the Cardiac Arrhythmia Service at the Na Homolce Hospital in Prague, Czech Republic.  

The patient was considered at high risk, having previously suffered both a massive heart attack and a stroke. He had been treated for hypertension for 8 years and had an average blood pressure during the day of 182/94 and 166/85 during the night despite treatment with five different medications.  Using an irrigated magnetic catheter and an advanced electroanatomic mapping system, Prof. Neuzil was able to accurately map both left and right renal arteries and deliver precise lesions to disengage the sympathetic nerve endings.  A follow up visit at 3 months after the procedure demonstrated that this patient's average blood pressure had been reduced to 153/78 during the day and 148/75 at night.

An increase in activity of the sympathetic nerves leading to the kidneys is a key factor in the development of hypertension.  The consequences of this increased nerve activity include sodium and water retention, increased enzyme release, and a change in the blood flow to the kidneys, all of which are associated with an increase in blood pressure.  Using advanced catheter navigation techniques, interventional physicians are able to disable the sympathetic nerves by delivering bursts of radiofrequency energy to the inside of the renal arteries.  This technique, called "denervation," has been shown to significantly reduce blood pressure and minimize or eliminate the need for medication.

"Stereotaxis' i
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Stereotaxis to Report Fourth Quarter and Full Year 2010 Financial Results and Conduct Conference Call on February 28, 2011
2. Stereotaxis Announces CE Mark and First Human Case for Vdrive™
3. Stereotaxis Announces Expansion of Catheter Strategic Partnership
4. Stereotaxis Announces Global Initial Training Site at University of Chicago
5. Stereotaxis Completes $40 Million Credit Facility
6. Stereotaxis Announces Public Offering of Common Stock
7. Stereotaxis Receives Commitment to Increase and Extend Credit Facility
8. Stereotaxis Awarded $1.5 Million in Grants under the Qualifying Therapeutic Discovery Project Program
9. Stereotaxis Reports Third Quarter Financial Results
10. Stereotaxis Appoints Industry Veteran as Head of EMEA Sales and Operations
11. Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
(Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3
... MONICA, Calif., May 8, 2012 Reprints Desk, Inc., ... and first sale of its new mobile-web application ... iPads, mobile devices, product websites, and portals for ... Article Viewer for use by companies in Pharmaceuticals, Biotechnology, ...
... PHILADELPHIA, May 8, 2012  The new prescription sleep aid ... and only prescription sleep aid approved by the U.S. ... insomnia when a middle-of-the-night awakening is followed by difficulty ... four hours of bedtime remaining before the planned time ...
Cached Medicine Technology:Medical Reprints Deployment on iPads and Websites Made Easier with New ePrints Mobile-Web App from Reprints Desk 2Medical Reprints Deployment on iPads and Websites Made Easier with New ePrints Mobile-Web App from Reprints Desk 3Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 2Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 3Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 4Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 5Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 6
(Date:8/21/2014)... Strongly influenced by their self-interest, ... there are no consequences, researchers in Georgia State ... This could imply that humans are less concerned ... researchers said. Their findings are published in the ... of unfairness is affected by their self-interest, indicating ...
(Date:8/21/2014)... August 21, 2014 Local agencies in ... larger discounts for specific protection plans, according to released ... consumers to quote life insurance from local agencies using ... local agents that appear inside of the national system ... method of price reviews this year. Adults who enter ...
(Date:8/21/2014)... The “Proteomics Market by Technology (Protein ... Plasmon Resonance, X-ray Crystallography) - Instruments, Reagents & ... studies the major market drivers, restraints, and opportunities ... of the World (RoW) , Browse 138 market ... and in-depth TOC on “Proteomics Market by Technology ...
(Date:8/21/2014)... Vegas, NV (PRWEB) August 21, 2014 ... the Association for Packaging and Processing Technologies. They ... It’s the view into a whole new world ... of engaged attendees, interactive education, and the latest ... lifecycle solutions from exhibitors. This year at Pack ...
(Date:8/21/2014)... 21, 2014 Today, Zane Benefits, the ... the premium tax credits in 2015. , According to ... part of the Affordable Care Act (ACA), premium tax ... individual health insurance through the Health Insurance Marketplaces. , ... and the amount of the tax credits, updated for ...
Breaking Medicine News(10 mins):Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 2Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 5Health News:Absolute I&D Provides Discounted Labor for Pack Expo Chicago 2
... of U.S. patents, has expanded its free offerings, providing access ... host of other improvements, making it even easier to find and ... ... 9, 2008 -- PatentStorm , the searchable website of millions ...
... and lay the groundwork for Phase 2 trials ... Leukemia (AML) settings , , ... Pharmaceuticals today announced that a Phase 1 dose ... the recommended dose for Phase 2 studies and ...
... today that a total of,20 U.S. and global abstracts ... presentation at the 2008 San Antonio,Breast Cancer Symposium (SABCS) ... breast cancer to be presented on Sunday, December,14, by ... Two U.S. abstracts to be presented ...
... Dec. 9 Frost & Sullivan, a global ... recently held Manufacturing Summit, hosted the India Manufacturing ... Bangalore. Instituted in 2004, the awards aim to ... manufacturing capabilities and acknowledge the best facilities in ...
... an extended period of time when parents grappling with the natural grief ... 10 ways relatives and friends can make the holidays just a little ... Friends, the world,s largest self help support organization with more than 600 ... ...
... leading FDA software development company - provides medical device makers with ... technical report, available now. , ... (PRWEB) December 9, ... software development company Full Spectrum informs medical device ...
Cached Medicine News:Health News:PatentStorm Releases U.S. Patent Applications and Other Features 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 3Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 4Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 5Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 2Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 3Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 2Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 3Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 4Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 5Health News:Ten Ways You Can Help a Family During the Holidays After a Child Dies 2Health News:Aimed at Medical Device Makers, FDA Software Development Company Full Spectrum Releases Free Technical Report on Software Protection Technology 2
... 2.0 is a reagent and probe system ... The high throughput plate based system is ... provides a unique approach for RNA detection ... using branched DNA (bDNA) technology. Branched DNA ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
...
Medicine Products: